使用人工网络预测辅助生殖治疗结局(FORTUNE)分类系统:预测IVF患者整倍体囊胚获得数的新预后模型
该研究基于2020至2023年10774个IVF周期开发FORTUNE模型,按预测整倍体囊胚获得数将患者分为五个预后组,并在2024年2089个周期中完成时间验证。模型对≥1、≥2、≥3个整倍体囊胚的预测AUC分别为0.834、0.849、0.861,各组无整倍体囊胚概率从极差组的98.3%到极好组的4.7%。
要点
- FORTUNE模型纳入女方年龄、伴侣年龄、AMH、窦卵泡计数和BMI,预测整倍体囊胚获得数。
- 五个预后组无整倍体囊胚概率:极差组98.3%、差组80.2%、临界组47.5%、好组15.8%、极好组4.7%。
- 时间验证队列中无整倍体囊胚率分别为极差组100.0%、差组82.6%、临界组47.4%、好组13.1%、极好组4.4%。
核心结论
- 该新型分类系统可为IVF患者提供关于预期整倍体囊胚获得数的客观、个体化咨询,有助于更好地决策治疗方案和计划刺激周期数。
研究设计与样本
- 回顾性分析2020至2023年8256对夫妇的10774个IVF周期,均对所有可用囊胚行PGT-A,并采用2024年2089个周期进行时间验证。
- 预测模型使用位置、尺度和形状的广义加性模型开发,采用穷尽5折交叉验证,并用校准图和判别指标评估模型性能。
主要发现
- 女方年龄中位数36.3岁(IQR:33.3-39.5),AMH中位数2.0 ng/ml(IQR:1.0-3.8)。
- 预测≥1、≥2、≥3个整倍体囊胚的模型在5折交叉验证中平均AUC分别为0.834、0.849、0.861。
- 训练集与交叉验证集间收缩可忽略(<1%),校准斜率平均值1.00(IQR:0.99-1.01),截距平均值0.015(IQR:0.00-0.03)。
- 开发队列中无整倍体囊胚概率:极差组98.3%、差组80.2%、临界组47.5%、好组15.8%、极好组4.7%。
- 获得≥3个整倍体囊胚的概率:极好组79.8%、好组43.7%、临界组8.9%、差组0.2%、极差组0%。
关键数值与推荐
- 时间验证集(n=2089)中无整倍体囊胚率:极差组100.0%、差组82.6%、临界组47.4%、好组13.1%、极好组4.4%。
- 时间验证集中获得≥3个整倍体囊胚率:极好组83.5%、好组51.0%、临界组10.7%、差组0.6%、极差组0.0%。
- FORTUNE模型可在https://epsilonkappa-analytics.shinyapps.io/FORTUNE及iOS App Store(https://apps.apple.com/en/app/fortune-ivf/id6747190429)使用并进一步验证。
临床怎么用
- 作者认为该分类系统可为IVF患者提供关于预期整倍体获得数的客观、个体化咨询,帮助决策治疗方案和计划刺激周期数。
局限性
- 单中心研究设计可能限制普适性。
- 模型未考虑实验室特异性因素或刺激方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Can a prediction model classify IVF patients into distinct prognostic groups based on their expected yield of euploid blastocysts? SUMMARY ANSWER: Five distinct prognostic groups were identified, with chance of obtaining at least one euploid blastocyst ranging from <1% to 2% in very poor to ∼95% in very good prognosis groups. WHAT IS KNOWN ALREADY: Euploid blastocyst yield is a critical determinant of IVF success. While female age strongly influences embryo euploidy, other factors like ovarian reserve markers, partner age, and BMI may also contribute. Current approaches rely on basic and somewhat arbitrary classification of ovarian reserve markers and patient age, which are unable to represent the granular multidimensional relationship between them. A systematic approach to classify patients based on their expected euploid yield would enable better treatment planning and patient counseling. STUDY DESIGN, SIZE, DURATION: A retrospective analysis of 10 774 IVF cycles from 8256 couples undergoing pre-implantation genetic testing for aneuploidy (PGT-A) of all available blastocysts from years 2020 to 2023 and a temporal validation cohort of 2089 cycles of 2089 patients from year 2024. The prediction model was developed using generalized additive models for location, scale, and shape using a development cohort from 2020 to 2023, and cross-validated through exhaustive 5-fold cross-validation. Temporal validation was performed using an entirely separate cohort from 2024. Model performance was assessed through calibration plots and discrimination metrics. PARTICIPANTS/MATERIALS, SETTING, METHODS: Couples undergoing IVF with PGT-A of all their available blastocysts were included. Model included female age, partner age, anti-Müllerian hormone (AMH), antral follicle count, and BMI as predictors. Non-linear associations were captured using neural networks and restricted cubic splines. Missing data were handled using multivariate imputation by chained equations. MAIN RESULTS AND THE ROLE OF CHANCE: The median female age was 36.3 years (IQR: 33.3-39.5) and AMH was 2.0 ng/ml (IQR: 1.0-3.8). Models for predicting ≥1, ≥2, and ≥3 euploid blastocysts yield achieved very good discrimination performance in 5-fold cross-validation samples with mean AUCs of 0.834, 0.849, and 0.861, respectively. Models showed negligible shrinkage (<1%) between training and cross-validation sets with near-perfect calibration slopes (mean: 1.00, IQR: 0.99-1.01) and intercepts (mean: 0.015, IQR: 0.00-0.03). Using predicted absolute counts of euploid blastocysts, five distinct prognostic groups were created based on predicted euploid blastocyst yield. Patients in the very poor prognosis group had 98.3% probability of obtaining no euploid blastocysts after stimulation while the probabilities were 80.2%, 47.5%, 15.8%, and 4.7% in poor, borderline, good, and very good prognosis groups. The chances of obtaining ≥3 euploid blastocysts were 79.8%, 43.7%, 8.9%, 0.2%, and 0% in very good, good, borderline, poor, and very poor prognosis groups. In the temporal validation set (n = 2089), which constituted the first cycles of patients that were treated, the rates of no euploid blastocysts obtained at the end of stimulation were 100.0%, 82.6%, 47.4%, 13.1%, and 4.4% in the very poor, poor, borderline, good, and very good prognosis groups. The rates of three or more euploid blastocysts obtained at the end of stimulation in the temporal validation set were 83.5%, 51.0%, 10.7%, 0.6%, and 0.0% for very good, good, borderline, poor, and very poor prognosis groups. The FORTUNE (Forecasting Outcomes of Reproductive Treatments Using artificial Networks) model is available for use and further validation at https://epsilonkappa-analytics.shinyapps.io/FORTUNE and App Store for iOS mobile devices https://apps.apple.com/en/app/fortune-ivf/id6747190429. LIMITATIONS, REASONS FOR CAUTION: Single-center study design may limit generalizability. The model does not account for laboratory-specific factors or stimulation protocols. WIDER IMPLICATIONS OF THE FINDINGS: This novel classification system provides objective, personalized counseling for IVF patients regarding expected euploid yield, enabling better-informed decision-making about treatment options and number of planned stimulation cycles. STUDY FUNDING/COMPETING INTEREST(S): There was no funding needed for this study. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. TRIAL REGISTRATION NUMBER: N/A.
引用
- Seli E, Kalafat E, Reig A, et al. Forecasting Outcomes of Assisted Reproductive Treatments Using Artificial Networks (FORTUNE) classification system: a new prognostic model to predict euploid blastocyst yield in patients undergoing IVF. Hum Reprod. 2025. PMID: 40889782. doi:10.1093/humrep/deaf163
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。